The Beatson Institute for Cancer Research, Garscube Estate, Glasgow, UK.
Cell Res. 2011 Apr;21(4):666-82. doi: 10.1038/cr.2010.154. Epub 2010 Nov 16.
The central arbiter of cell fate in response to DNA damage is p53, which regulates the expression of genes involved in cell cycle arrest, survival and apoptosis. Although many responses initiated by DNA damage have been characterized, the role of actin cytoskeleton regulators is largely unknown. We now show that RhoC and LIM kinase 2 (LIMK2) are direct p53 target genes induced by genotoxic agents. Although RhoC and LIMK2 have well-established roles in actin cytoskeleton regulation, our results indicate that activation of LIMK2 also has a pro-survival function following DNA damage. LIMK inhibition by siRNA-mediated knockdown or selective pharmacological blockade sensitized cells to radio- or chemotherapy, such that treatments that were sub-lethal when administered singly resulted in cell death when combined with LIMK inhibition. Our findings suggest that combining LIMK inhibitors with genotoxic therapies could be more efficacious than single-agent administration, and highlight a novel connection between actin cytoskeleton regulators and DNA damage-induced cell survival mechanisms.
细胞命运的中央仲裁者是 p53,它调节与细胞周期阻滞、存活和凋亡相关的基因表达。尽管已经描述了许多由 DNA 损伤引发的反应,但肌动蛋白细胞骨架调节剂的作用在很大程度上尚不清楚。我们现在表明,RhoC 和 LIM 激酶 2(LIMK2)是由遗传毒性药物诱导的 p53 的直接靶基因。尽管 RhoC 和 LIMK2 在肌动蛋白细胞骨架调节中具有既定的作用,但我们的结果表明,LIMK2 的激活在 DNA 损伤后也具有促生存功能。通过 siRNA 介导的敲低或选择性药理学阻断 LIMK 的抑制作用使细胞对放射或化学疗法敏感,使得单独使用时亚致死的治疗方法与 LIMK 抑制联合使用时导致细胞死亡。我们的研究结果表明,将 LIMK 抑制剂与遗传毒性疗法相结合可能比单独使用一种药物更有效,并强调了肌动蛋白细胞骨架调节剂与 DNA 损伤诱导的细胞存活机制之间的新联系。